Anixa Biosciences (NASDAQ:ANIX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Anixa Biosciences (NASDAQ:ANIX) from a sell rating to a hold rating in a research report released on Saturday morning.

A number of other research analysts also recently issued reports on ANIX. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Friday, December 12th. Zacks Research downgraded Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Anixa Biosciences currently has an average rating of “Hold” and an average target price of $9.00.

Anixa Biosciences Stock Down 0.9%

Shares of NASDAQ ANIX opened at $3.19 on Friday. The firm’s fifty day moving average is $3.88 and its 200 day moving average is $3.60. Anixa Biosciences has a 52 week low of $2.33 and a 52 week high of $5.46. The company has a market cap of $106.48 million, a price-to-earnings ratio of -9.11 and a beta of 0.49.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Monday, January 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). Equities research analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock valued at $4,694,000 after buying an additional 29,436 shares during the period. Bank of America Corp DE lifted its position in Anixa Biosciences by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after acquiring an additional 3,645 shares during the period. Citadel Advisors LLC boosted its stake in Anixa Biosciences by 31.6% during the third quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock worth $317,000 after acquiring an additional 23,072 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Anixa Biosciences by 4.9% during the third quarter. GSA Capital Partners LLP now owns 81,897 shares of the company’s stock worth $270,000 after acquiring an additional 3,790 shares in the last quarter. Finally, Susquehanna International Group LLP grew its holdings in Anixa Biosciences by 378.4% in the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after purchasing an additional 63,584 shares during the period. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.